Compare Diageo plc (DEO) vs Hims and Hers Health Inc (HIMS) Price & Performance

Diageo (DEO) trades at $96.35, up 3.83% with bullish technical signals from moving averages. The company reported mixed FY2026 results with a 2% organic sales decline but 2% operating profit growth, supported by cost savings. Analyst consensus leans positive with 48.65% buy ratings, though valuation metrics appear elevated with a P/E of 31.16. Recent news highlights a $1 billion cost-cutting plan and strategic focus on spirits and Guinness to drive turnaround.

The outlook is cautiously optimistic with management's restructuring program expected to improve margins and cash flow. Key risks include ongoing weakness in North American markets and competitive pressures. Wall Street sees potential upside with recent target increases, but investors should monitor execution of the turnaround plan amid challenging market conditions.

Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.

The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.